Do you have a fever, rash, or flu-like symptoms?

Have you recently been exposed to HIV? Not sure?

Call us to learn more about our Acute HIV studies
(212) 305-7897.

Click here to get information on our Acute HIV Community Advisory Board


Acute HIV Treatment Studies

Don't Miss the Diagnosis

Acute HIV-1 infection is an often-misdiagnosed cause of an acute flu-like or mono-like illness. Recognition has important implications in terms of treatment and prevention of transmission.

Referral for Acute HIV-infection testing should be considered in patients with a recent history of unprotected sexual activity, needle sharing, or other potential exposure to HIV

And

Have the presence of one or more of the following signs and symptoms:

  • Fever
  • Rash
  • Lymphadenopathy
  • Oral, Genital, or Rectal Ulcers
  • Exudative Pharyngitis
  • Aseptic Meningitis Headache, Photophobia, Stiff Neck)
  • Myalgia/Arthralgia
  • Fatigue
  • Weight Loss
  • Night Sweats
  • Anorexia

 

For Healthcare Providers

If you have a patient with a history of possible exposure to HIV

And

Symptoms consistent with early HIV infection, our project offers HIV counseling and screening through a research protocol.

Diagnosis of early HIV infection is made on the basis of the standard ELISA/Western Blot and HIV RNA PCR (viral load), which is currently not an approved test for diagnosis of acute HIV outside of a research study.

Current Studies\

Treatment Naïve


Treatment Naïve

Studies in this section are for people who have never taken HIV medications before.

 

Study Number A5217
Study Name

The SETPOINT Study – A Randomized Study of the Effect of Immediate Treatment with Potent Antiretroviral Therapy versus Observation with Treatment as Indicated in Newly Infected HIV-1-infected Subjects: Does Early Therapy Alter the Virologic Setpoint?

Description

The goal of this study is to determine whether immediate, short-term therapy (9 months of anti-HIV medications) for people with recently acquired HIV infection, is beneficial as opposed to delaying therapy until standard criteria for treatment are met. 

 

Volunteers who have been infected with HIV within approximately 6 months will be randomized (assigned by chance, like flipping a coin) into one of two groups:

 

Group 1

Truvada® and Kaletra® for 36 weeks

 

Group 2

No treatment unless HIV progression occurs

 

The study will determine whether the viral load 72 weeks into the study is lower in people who received treatment initially.  Any volunteer who meets standard criteria for treatment will be offered HIV treatment.
Who Is Eligible Persons at least 18 years of age who were infected with HIV within approximately 6 months, with T cells (CD4 count) >350 cells/mm3 and plasma HIV-1 RNA >500 copies/mL
For More Information Call (212) 305-7897 or e-mail

back to top